These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27663474)

  • 1. Theory and practice of clinical pharmacodynamics in oncology drug development.
    Parchment RE; Doroshow JH
    Semin Oncol; 2016 Aug; 43(4):427-35. PubMed ID: 27663474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The root causes of pharmacodynamic assay failure.
    Ferry-Galow KV; Makhlouf HR; Wilsker DF; Lawrence SM; Pfister TD; Marrero AM; Bigelow KM; Yutzy WH; Ji JJ; Butcher DO; Gouker BA; Kummar S; Chen AP; Kinders RJ; Parchment RE; Doroshow JH
    Semin Oncol; 2016 Aug; 43(4):484-91. PubMed ID: 27663480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials.
    Kummar S; Do K; Coyne GO; Chen A; Ji J; Rubinstein L; Doroshow JH
    Semin Oncol; 2016 Aug; 43(4):446-52. PubMed ID: 27663476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.
    Parchment RE; Doroshow JH
    Semin Oncol; 2016 Aug; 43(4):514-25. PubMed ID: 27663483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pragmatic issues in biomarker evaluation for targeted therapies in cancer.
    de Gramont A; Watson S; Ellis LM; Rodón J; Tabernero J; de Gramont A; Hamilton SR
    Nat Rev Clin Oncol; 2015 Apr; 12(4):197-212. PubMed ID: 25421275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations.
    Kinders R; Ferry-Galow K; Wang L; Srivastava AK; Ji JJ; Parchment RE
    Clin Cancer Res; 2014 May; 20(10):2578-86. PubMed ID: 24831280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies.
    Calvo E; Walko C; Dees EC; Valenzuela B
    Am Soc Clin Oncol Educ Book; 2016; 35():e175-84. PubMed ID: 27249721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based laboratory medicine in oncology drug development: from biomarkers to diagnostics.
    Modur V; Hailman E; Barrett JC
    Clin Chem; 2013 Jan; 59(1):102-9. PubMed ID: 23034140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioanalytical aspects of clinical mass balance studies in oncology.
    Dubbelman AC; Rosing H; Schellens JH; Beijnen JH
    Bioanalysis; 2011 Dec; 3(23):2637-55. PubMed ID: 22136052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted approaches to childhood cancer: progress in drug discovery and development.
    Hirsch S; Marshall LV; Carceller Lechon F; Pearson AD; Moreno L
    Expert Opin Drug Discov; 2015 May; 10(5):483-95. PubMed ID: 25840490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncologic phase 0 trials incorporating clinical pharmacodynamics: from concept to patient.
    Doroshow JH; Parchment RE
    Clin Cancer Res; 2008 Jun; 14(12):3658-63. PubMed ID: 18559579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
    Tan DS; Thomas GV; Garrett MD; Banerji U; de Bono JS; Kaye SB; Workman P
    Cancer J; 2009; 15(5):406-20. PubMed ID: 19826361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translating pharmacodynamic biomarkers from bench to bedside: analytical validation and fit-for-purpose studies to qualify multiplex immunofluorescent assays for use on clinical core biopsy specimens.
    Marrero A; Lawrence S; Wilsker D; Voth AR; Kinders RJ
    Semin Oncol; 2016 Aug; 43(4):453-63. PubMed ID: 27663477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials.
    Ang JE; Kaye S; Banerji U
    Curr Drug Targets; 2012 Nov; 13(12):1525-34. PubMed ID: 22974395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioanalysis in oncology drug discovery.
    Srinivas NR; Mullangi R
    Biomark Med; 2015; 9(9):877-86. PubMed ID: 26328779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic biomarkers for molecular cancer therapeutics.
    Sarker D; Workman P
    Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive genomic biomarkers.
    Kumar R; Amado RG
    Curr Top Microbiol Immunol; 2012; 355():173-88. PubMed ID: 21877260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
    Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
    Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical parameters in targeted drug development: the pharmacological audit trail.
    Banerji U; Workman P
    Semin Oncol; 2016 Aug; 43(4):436-45. PubMed ID: 27663475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.